Ranbaxy Laboratories' wholly owned subsidiary Ranbaxy Pharmaceuticals Canada Inc. (RPCI), has received an approval on December 24, 2013 to manufacture and market RAN-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health Canada.
The total market size of Aricept (Donepezil Hydrochloride) in Canada is $153.9 million and growing at 38% (extended units). Donepezil Hydrochloride is indicated in the treatment of dementia in Alzheimer’s patients.
Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
